Browsing Category
Pharma Industry News
4729 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why Celcuity’s FDA priority review for gedatolisib could reset the breast cancer playbook
Celcuity earns FDA priority review for gedatolisib in advanced breast cancer. Find out what the July 2026 PDUFA date means for its market trajectory.
NK cell immunotherapy moves toward solid tumors as GT Biopharma files IND for GTB-5550 TriKE
Find out how NK cell immunotherapy is moving into solid tumors as GT Biopharma files an IND for its B7-H3-targeted TriKE GTB-5550.
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after positive Phase III trial
Akeso files gumokimab for NMPA review in ankylosing spondylitis. Find out how this move expands its autoimmune pipeline beyond oncology.
Positive early Phase 2 data strengthen Ocugen’s case for OCU410 in the fast-evolving dry AMD treatment market
Find out how Ocugen’s early Phase 2 data for OCU410 could reshape competition and investor sentiment in the fast-growing dry AMD treatment market.
Organon (NYSE: OGN) secures FDA approval for five-year use of NEXPLANON contraceptive implant, adding new REMS training requirement
Find out how Organon’s NEXPLANON just got FDA approval for five-year use—and what the new REMS program means for doctors and competitors.
Atossa Therapeutics (Nasdaq: ATOS) gains FDA orphan drug designation for (Z)-endoxifen in Duchenne muscular dystrophy
Find out how Atossa Therapeutics’ orphan drug nod for (Z)-endoxifen in Duchenne muscular dystrophy could reshape its R&D roadmap.
Genetic stratification reframes HMNC Brain Health’s BH-200 Phase 2b data and revives precision psychiatry strategy at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reframed clinical risk and revived precision psychiatry strategy in depression.
AGAMREE wins Swissmedic approval, positioning Santhera for broader Duchenne muscular dystrophy market expansion
Santhera wins Swissmedic approval for AGAMREE in Duchenne muscular dystrophy. Find out how this milestone could drive European expansion and investor sentiment.
AAVantgarde clears key execution hurdle as LUCE-1 Phase 1/2 study of AAVB-081 completes enrollment
Find out how AAVantgarde Bio’s LUCE-1 enrollment milestone reshapes the gene therapy landscape for Usher syndrome type B retinitis pigmentosa.
Vaxart advances oral vaccine platform with positive maternal and infant data from norovirus study
Find out how Vaxart advanced its oral vaccine platform with positive norovirus data showing maternal immune responses and antibody transfer to infants.